Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
PepGen CEO Caroline Godfrey profile image

BioEscalator resident and Oxford spin-out, PepGen, has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor. The University of Oxford and CureDuchenne, a leading patient advocacy group, also participated in the round.

PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that are designed to correct genetic defects in diseases with high unmet medical needs. PepGen’s proprietary PPMO technology will dramatically enhance the delivery of oligonucleotides to key tissues, while also improving safety compared with competing therapies.

 

“PepGen’s cell-penetrating peptide (CPP) technology represents an important step change in that we have succeeded in optimizing cellular uptake whilst simultaneously engineering out the safety signals that historically impacted earlier attempts at this approach,” said PepGen co-founder Matthew Wood, professor of neuroscience at the University of Oxford. “I am delighted to see our progress validated by support from top-tier investors, and look forward to seeing translation into the clinic.”

 

One of PepGen’s lead indications, DMD is a devastating genetic neuromuscular disorder affecting one in 3,500-5,000 male births around the world.

 

“Patients born with Duchenne muscular dystrophy lack dystrophin, a critical protein that confers structural integrity on muscle,” said Caroline Godfrey, PhD, CEO and co-founder of PepGen. “PepGen is developing unique, proprietary cell-penetrating peptides that we expect will improve upon the efficacy of existing exon-skipping approaches to restore dystrophin expression in DMD patients.”

 

A key benefit of PepGen’s platform is its unique potential to reach all the tissues affected by DMD and other inherited neuromuscular and cardiovascular conditions. Notably, unlike other approaches, PepGen’s drug candidates are strongly distributed to cardiac tissue. Heart disease is a key cause of morbidity and mortality in these devastating conditions.

 

“A unique distinction of the PepGen peptides is that they can penetrate cardiac tissue, addressing a major and growing problem DMD patients face as they get older,” said Ramin Farzaneh-Far, MD, venture partner at RA Capital Management, PepGen’s executive chair, and a board-certified cardiologist. “With the recent approvals of treatments that generate small increases in dystrophin in skeletal muscle, patients may be ambulating and living longer, but this, in turn, is expected to shift the burden of morbidity and mortality towards an epidemic of heart disease, which is not adequately addressed by current DMD therapies.”

 

Said Debra Miller, CEO of CureDuchenne Ventures: “PepGen, we believe, represents a potential breakthrough approach for which DMD patients and their caregivers have been hoping against hope. Virtually all Duchenne patients have cardiomyopathy, and cardiac failure is prevalent amongst this population, so therapies addressing this unmet need promise a major impact for the Duchenne community.”

 

In addition to DMD, PepGen has a pipeline of drugs targeting rare neuromuscular and neurologic diseases, with a particular focus on those with severe cardiac manifestations as well as primary cardiac conditions.

 

“We consider ourselves lucky to be a part of this unique story. The ability of this technology to deliver life-saving drugs to all the organs and tissues affected by these devastating diseases offers real hope for a total treatment of these conditions,” said Joshua Resnick, MD, managing director at RA Capital Management and member of the PepGen board of directors.

 

PepGen’s cell-penetrating peptide technology for oligonucleotide delivery was developed over more than a decade of research in the UK and arose from collaborations between the neuroscience laboratory of Professor Wood at the University of Oxford and the peptide chemistry laboratory of Dr Mike Gait at the MRC Laboratory of Molecular Biology in Cambridge.

 

With a seed investment of £4.5 million from OSI, PepGen was spun out in 2018 to commercialize the cell-penetrating peptide platform. The company was additionally supported by a prestigious £1.6 million grant from Innovate UK, the UK’s innovation agency.

 

“Delivery is a challenge many innovative therapeutic platforms face; we’re proud of the team’s achievements to date as PepGen’s CPP technology opens up a broad set of opportunities in gene therapy and gene modulation,” said Uciane Scarlett, PhD, OSI’s investment principal.

 

Christopher Ashton, PhD, advisor to OSI, will continue to serve on PepGen’s board of directors.

 

PepGen’s new corporate headquarters will be in Boston, and its research hub will continue in the UK.

 

Original Press Release